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Background: Accumulating preclinical and clinical evidence implicates epithelial-mesenchymal transition (EMT) in
acquired resistance to anticancer drugs; however, mechanisms by which the mesenchymal state determines drug
resistance remain unknown.
Results: To explore a potential role for altered cellular metabolism in EMT and associated drug resistance, we
analyzed the metabolome and transcriptome of three lung cancer cell lines that were rendered drug resistant
following experimental induction of EMT. This analysis revealed evidence of metabolic rewiring during EMT that
diverts glucose to the TCA cycle. Such rewiring was at least partially mediated by the reduced expression of
pyruvate dehydrogenase kinase 4 (PDK4), which serves as a gatekeeper of the TCA cycle by inactivating pyruvate
dehydrogenase (PDH). Overexpression of PDK4 partially blocked TGFβ-induced EMT; conversely, PDK4 inhibition via
RNAi-mediated knockdown was sufficient to drive EMT and promoted erlotinib resistance in EGFR mutant lung
cancer cells. We identified a novel interaction between PDK4 and apoptosis-inducing factor (AIF), an inner
mitochondrial protein that appears to play a role in mediating this resistance. In addition, analysis of human tumor
samples revealed PDK4-low as a predictor of poor prognosis in lung cancer and that PDK4 expression is dramatically
downregulated in most tumor types.
Conclusions: Together, these findings implicate PDK4 as a critical metabolic regulator of EMT and associated drug
resistance.
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Acquired drug resistance has emerged as a major chal-
lenge to effective cancer therapy. Tumor-targeted ther-
apies, such as anti-EGFR treatments for lung cancer and
anti-HER2 treatments for breast cancer, are highly ef-
fective in disease management in biomarker-defined pa-
tient populations. However, the vast majority of these
treated patients’ cancers ultimately become drug resistant
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unless otherwise stated.cells that survive the therapy and repopulate the relapsed
tumor, thereby limiting the long-term effectiveness of
these targeted agents [1].
Epithelial-mesenchymal transition (EMT) is a bio-
logical process during which epithelial cells lose the ex-
pression of epithelial markers and gain the expression of
mesenchymal markers, imparting cells with distinct mor-
phological, migratory and other properties. EMT has fre-
quently been observed in drug-resistant cancer cells in
both preclinical models and clinical samples [2], including
resistance to anti-EGFR therapy in lung cancer [3,4], re-
sistance to androgen-deprivation therapy in prostate can-
cer [5], and resistance to chemotherapy in breast cancer. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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converts epithelial cancer cells into a more metastatic and
“stem-like” state [7].
Altered metabolism has been recognized as a hallmark of
cancer [8]. Tumor cells need to consume more glucose and
glutamine to satisfy the energy demand and biosynthesis re-
quirement for rapid proliferation. Although considered as
auxiliary to tumorigenesis for many years, recent studies
have revealed oncogenic mutations in the core metabolism
network that could potentially drive tumor initiation and
progression [9]. In addition, accumulating evidence has
revealed that altered metabolism is essential for activated
oncogenes and inactivated tumor suppressors to drive
malignant transformation [10]. Considering the profound
changes in cellular metabolism in cancer, we hypothesized
that tumors with acquired drug resistance might resort to
alternative mechanisms to fuel their growth and survival
under drug treatment. In this study, we report a diversion
of glucose metabolism towards the TCA cycle during EMT
in cancer cells. We also provide evidence that pyruvate de-
hydrogenase kinase 4 (PDK4) is a critical regulator of EMT
and associated drug resistance.
Methods
Antibodies and other reagents
Antibodies used are listed as follows: E-cadherin (Cell
Signaling, 24E10), N-cadherin (Cell Signaling, no. 4061);
Vimentin (Cell Signaling, D21H3), GAPDH (Cell Signaling,
14C10), Zeb1 (Cell Signaling, D80D3), Snail (Cell Signal-
ing, C15D3), VDAC (Cell Signaling, D73D12), apoptosis-
inducing factor (AIF) (Cell Signaling, D39D2), and FLAG
(Sigma, M2). PDK4 polyclonal antibody was generated by
immunizing rabbits against a peptide corresponding to
amino acids 264–277 of human PDK4 (VEHQENQPSLT-
PIE) (Yenzyme).
Cell culture
Unless otherwise specified, all cell lines were cultured in
RPMI1640 (Gibco) containing 2 g/l sodium bicarbonate,
10% FBS, 2 mM P/S, and 4 mM glutamine (Gibco). To
generate the TGFβ-induced mesenchymal cells, cells were
cultured in the presence of 2 ng/ml TGFβ (Cell signaling)
for 2 to 5 weeks. A549 cells were cultured with TGFβ for
2 to 3 weeks. HCC827 and NCI-H358 cells were cultured
with TGFβ for 3 to 5 weeks prior to experiments. Fresh
media containing TGFβ was replenished every 3–4 days.
The day before the experiment, cells were re-seeded in the
appropriate plates without TGFβ. Cell lines are main-
tained by a core facility at Genentech that routinely uses
STR fingerprinting to verify cell line identity.
Data analysis
Unless otherwise specified, all data plotting and statis-
tical analysis was performed using Prism Graph Pad 5.0,and the error bars represent SEM. Student's t test was
used to assess the statistical significance of the differ-
ences between groups (two-tail *p value <0.05; two-tail
**p value <0.01.
Survival analyses were performed with the Kaplan-
Meier method and Cox proportional-hazard model. Re-
sults across the three data sets (GSE42127, GSE8894,
and GSE3141) were combined in a meta-analysis, using
the R package meta. The overall combined estimate of
the hazard ratio was obtained from their values and
standard errors in the individual data sets.
PDK4 expression data in normal lung, lung adenocar-
cinoma and squamous cell carcinoma of the lung was
generated from TCGA RNA-seq data, which was ob-
tained from the Cancer Genomics Hub at UC Santa
Cruz and preprocessed and aligned with HTSeqGenie
[11]. PDK4 expression data in multiple cancer indica-
tions was from the Gene Logic database of microarray
data using GeneChip human genome U133 Plus 2.0 array
(Affymetrix). Expression summary values for all probe sets
were calculated using the RMA algorithm as implemented
in the affymetrix package from Bioconductor.
Global metabolomic profiling
The parental and TGFβ-induced mesenchymal cells were
rinsed with PBS, scraped in PBS, and spun down. The cell
pellets were snap-frozen and submitted to Metabolon Inc
for global metabolomic analysis [12]. Briefly, a combination
of GC-MS and LC-MS methods were used, and each me-
tabolite amount was normalized to total protein amount of
the individual cell pellets. Each sample consisted of cells
collected from two 15-cm plates at approximately 60%
confluence, and each condition included five replicates.
Glycolysis/OXPHOS ratio measurement
Real-time Glycolysis/OXPHOS rate was measured using
the Seahorse metabolic analyzer, following manufacturer's
protocols. Briefly, cells were plated in six replicates in
96-well Seahorse assay plates. The seeding cell numbers
were adjusted based on cell growth rate, with the goal to
reach similar cell density at the time of the real-time
measurement. The next day, cells were washed twice and
incubated in 100 μl of modified RPMI1640 growth media
for 2 h. The modified RPMI1640 growth media did not
contain sodium bicarbonate, and contained dialyzed
FBS (Gibco) instead of standard FBS. Proton production
rate (PPR) and oxygen consumption rate (OCR) were
recorded.
Mass isotopologue distribution analysis using C-13 stable
isotopes
Cells were plated in a 15-cm plate overnight, and then
switched to tracing media. The tracing media was based
on standard RPMI1640 growth media containing 10%
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U5-glutamine or glucose substituted by 13C-U6-glucose
(Cambridge Isotope). After being cultured in the tracing
media for 24 h, cells were harvested and processed for
mass spectrometry. A detailed description of the mass
spectrometry analysis is provided in ‘Extended Methods.’
Microarray gene expression analysis
Gene expression profiling comparing TGFβ-treated mes-
enchymal cells and corresponding parental cells was per-
formed using GeneChip human genome U133 Plus 2.0
array (Affymetrix), following standard protocols. Data
were normalized using the R package RMA from Bio-
conductor and analyzed with the R limma package. The
expression microarray data has been deposited in the
Gene Expression Omnibus (GEO) database under acces-
sion number GSE49644.
Extended methods
Description of additional methods is provided in Additional
file 1.
Results
Experimentally-induced EMT in lung cancer cell lines is
associated with metabolic reprogramming
Human cancer cell lines provide essential models for
dissecting fundamental mechanisms in tumor biology.
We modeled EMT in cultured cancer cells using TGFβ
treatment since TGFβ robustly induces EMT in many
epithelial cell line models, and physiologically, hyperacti-
vation of TGFβ signaling has been shown to be associ-
ated with the mesenchymal phenotype and cancer drug
resistance [13,14]. To identify EMT-associated changes
in cancer cell biology that are not restricted to one specific
genetic background, we examined three different human
non-small cell lung cancer (NSCLC) cell lines—A549
(KRASG12S-driven), HCC827 (EGFRΔΕ746-A750-driven), and
NCI-H358 (KRASG12C-driven). We cultured cells with
continuous exposure to TGFβ for 3 weeks and observed
dramatic morphological transformation—the cells changed
from displaying a compact epithelial morphology with ob-
vious cell-cell contacts to a fibroblast-like morphology with
scattered spindle shapes (Figure 1A). Consistent with the
morphological changes observed in the TGFβ-treated cells,
we detected decreased expression of the epithelial marker
E-cadherin as well as increased expression of the mesen-
chymal markers N-cadherin and Vimentin and the EMT-
associated transcription factors Zeb1 and Snail (Figure 1B).
Consistent with previous studies implicating EMT in
drug resistance, the derived mesenchymal cells became
significantly less sensitive to targeted therapies. The mu-
tant EGFR-driven HCC827 parental cells were very sensi-
tive to erlotinib, whereas the TGFβ-induced mesenchymal
derivatives had lost their EGFR ‘addiction’ and becamelargely resistant to erlotinib (Figure 1C). Likewise, the
mesenchymal derivatives of A549 and NCI-H358 cells be-
came significantly less sensitive to the MEK inhibitor
GDC-0973 (Figure 1C) and KRAS inhibition via RNAi
(see Figure three F in reference [15]), respectively. Taken
together, these findings demonstrate an EMT upon
chronic TGFβ treatment of these ‘oncogene-addicted’
lung cancer cells and provide a model system for studying
the role of EMT in mediating drug resistance in vitro.
In the course of culturing these cells, we observed
slower acidification of the media in the mesenchymal de-
rivatives relative to the corresponding untreated parental
cell lines, suggesting a possible metabolic rewiring event
during EMT. A switch from oxidative phosphorylation
(OXPHOS) to aerobic glycolysis, the so-called Warburg
effect, is a key feature of many cancer cells [16]. Whereas
glycolysis is a relatively rapid mechanism by which cells
can produce ATP, OXPHOS is much more energy effi-
cient as it produces more ATP per glucose molecule. We
therefore measured real-time glycolysis and OXPHOS
levels in these cells and observed a consistent decrease in
the glycolysis/OXPHOS ratio upon EMT in all three cell
lines (Figure 1D). Moreover, this glycolysis-to-OXPHOS
switch was not restricted to TGFβ-induced EMT: EGFR-
mutant HCC4006 cells that had been selected for resist-
ance to erlotinib and which gained mesenchymal features
[17], similarly, exhibited a decreased glycolysis/OXPHOS
ratio relative to their parental, erlotinib-sensitive counter-
part (Additional file 2: Figure S1A). These collective data
reveal a metabolic remodeling process commensurate
with EMT.
Metabolomic profiling reveals amino acid accumulation
associated with EMT
The observed glycolysis-to-OXPHOS switch during EMT
prompted us to examine the global metabolomic profiles
of these cells before and after EMT using mass spectrom-
etry (Additional file 3: Table S1). Using an absolute fold-
change >2 and a p value <0.05 as the cutoff, we observed
only ten metabolites (out of approximately 400 known
metabolites measured) that showed consistently signifi-
cant changes during EMT across all three cell lines
(Additional file 2: Figure S1B). Among them, five me-
tabolites—glutamine, tryptophan, reduced glutathione,
4-guanidinobutanoate, and cysteinylglycine—belong to
the amino acid or peptide category. We further exam-
ined the levels of the 20 standard amino acids before
and after EMT and found an overall increase in amino
acid levels in the mesenchymal cells in all three models
(Additional file 2: Figure S1C).
We were particularly intrigued by the observed changes
in glutamine (Figure 1E) and glutamate (Figure 1F) due to
the direct interconversion between these two metabolites.
The accumulation of intracellular glutamate was not due
Figure 1 (See legend on next page.)
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Figure 1 Metabolic changes in three NSCLC cell lines upon TGFβ-induced EMT. A549, HCC827, and NCI-H358 lung cancer cells were
cultured in the presence of 2 ng/ml TGFβ for 2 to 5 weeks to induce EMT. The following aspects of both the parental (P) and mesenchymal (M)
cells were characterized. (A) Morphological changes of cells. (B) The expression of the epithelial marker (E-cadherin) and mesenchymal markers
(N-cadherin, Vimentin, Zeb1, and Snail). (C) Erlotinib sensitivity of HCC827 and GDC-0973 sensitivity of A549 parental and mesenchymal cells. The
cells were treated with the EGFR kinase inhibitor erlotinib or MEK inhibitor GDC-0973 for 3 days, and viability was measured using a CellTiter-Glo
assay. (D) Glycolysis/OXPHOS ratio, defined by PPR/OCR and measured using the Seahorse metabolic analyzer. Average results from three to four
independent experiments are shown. (E, F) Cellular glutamine (E) and glutamate (F) concentrations as measured by mass spectrometry. Each
data point is from five separate biological samples generated at the same time. The boxes represent 10–90 percentile. (G) Glutamate secretion
per cell during 24 h. Average of data from six wells in one experiment, which is representative of three independent experiments, is shown.
(H, I) Cells were incubated with growth media containing 13C-U-glucose overnight, and then subjected to LC-MS analysis. (H) Glucose to
glutamate contribution was plotted based on the percentage of (M + 2) glutamate in the total glutamate pool. (I) Glucose to TCA cycle
contribution was plotted based on the percentages of (M + 2) citrate, (M + 2) α-ketoglutarate and (M + 2) malate in each individual metabolite’s
total pool. For all panels, data are plotted as mean ± SEM. *p < 0.05; **p < 0.01, unless otherwise specified.
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nificant (p < 0.01) increase in glutamate secretion across
all three mesenchymal cell populations relative to their
corresponding parental controls (Figure 1G). Notably, al-
though the TGFβ-treated cells grew about two fold slower
than their parental counterparts (Additional file 2: Figure
S1D), it is unlikely that the observed glutamate accumula-
tion is simply a consequence of reduced proliferation rate
since metabolomic profiling of the NCI-60 cell line panel
did not reveal any association between glutamate accu-
mulation and cell proliferation rate [18]. Together, these
findings demonstrate glutamate accumulation associ-
ated with the conversion of epithelial cancer cells to a
mesenchymal state.
Glucose diversion to the TCA cycle contributes to
increased intracellular glutamate in mesenchymal cells
Next, we addressed the mechanism underlying the ob-
served glutamate accumulation in the mesenchymal
cells. The likely potential carbon sources are either glu-
tamine or glucose. Glutamine can be converted directly
to glutamate via deamination. Glucose, in contrast, can
be converted to glutamate through a multi-step process
[10]. During the early steps of glycolysis, glucose is first
converted to pyruvate and then to acetyl-CoA, which
directly enters the TCA cycle. Alpha-ketoglutarate, a
critical intermediate metabolite in the TCA cycle, serves
as the backbone for the synthesis of many amino acids,
including glutamate. To assess the glucose and glutam-
ine contributions to glutamate and glutathione, we per-
formed mass isotopologue distribution analysis (MIDA)
[19]. We cultured the epithelial and mesenchymal cells
with C-13 uniformly labeled glucose or glutamine, and
quantified the incorporation of C-13 label into glutamate
using liquid column-mass spectrometry (LC/MS). Al-
though glutamine was still a major source of the glutam-
ate pool in both the parental and mesenchymal cells, we
found significantly decreased percentages of glutamine-
derived glutamate (Additional file 2: Figure S1E) and
corresponding increased percentages of glucose-derivedglutamate (Figure 1H) in all three mesenchymal models
compared to their corresponding parental cells. Import-
antly, we also observed significantly increased percentages
of glucose-derived TCA cycle metabolites, including citrate
(the first metabolite in the TCA cycle), α-ketoglutarate
(αKG, a critical precursor for amino acid synthesis), and
malate (Figure 1I), consistent with the notion that the TCA
cycle contributes to the observed glutamate accumulation
during EMT. Collectively, these data demonstrate a diver-
sion of glucose to the TCA cycle→ glutamate axis in the
mesenchymal cells (Figure 2A).
PDK4 is downregulated in mesenchymal cells and
regulates glucose contribution to the TCA cycle
To further explore the molecular mechanisms underlying
the observed metabolic rewiring upon EMT, we compared
microarray gene expression profiles of A549, HCC827,
and NCI-H358 cells before and after EMT. Using an abso-
lute fold-change >5 and a FDR-adjusted p value <0.00001
as the cutoff, we observed approximately 30 metabolism-
associated genes that consistently demonstrated differen-
tial expression in all three mesenchymal and parental cell
line comparisons (Additional file 4: Figure S2A). Among
them, PDK4, but not the other related PDKs (PDK1-3),
was consistently and dramatically downregulated in all
three mesenchymal cell line models (Figure 2B).
The pyruvate dehydrogenase (PDH) complex is a mega-
protein complex that functions at the interface of glycoly-
sis and the TCA cycle, critically controlling entry into the
TCA cycle by catalyzing the conversion of pyruvate to
acetyl-CoA, thereby supplying acetyl-CoA to the TCA
cycle [20]. The regulatory mechanisms for PDH activity
include its inactivation by four kinases, PDK1-4, and its
activation by two phosphatases, PDP1-2 [21]. Decreased
expression of PDK4 would therefore be expected to acti-
vate PDH and divert glucose to the TCA cycle, consistent
with the observed diversion of glucose to TCA cycle/glu-
tamate (Figure 2A).
To validate the microarray findings, we confirmed the re-
duction in PDK4 expression in TGFβ-treated mesenchymal
Figure 2 (See legend on next page.)
Sun et al. Cancer & Metabolism 2014, 2:20 Page 6 of 14
http://www.cancerandmetabolism.com/content/2/1/20
(See figure on previous page.)
Figure 2 PDK4 downregulation is observed in mesenchymal cells, and mediates metabolic rewiring. (A) A schematic representation of
the metabolic rewiring observed in TGFβ-induced mesenchymal cells. Red highlight indicates increased flux from glucose to the TCA cycle and
then to glutamate in the mesenchymal cells. (B) Heatmap based on microarray gene expression data showing the mRNA levels of PDK1-PDK4 in
the parental cells (P) and mesenchymal derivatives (M). (C) Quantitative RT-PCR showing PDK4 mRNA levels in parental and mesenchymal cells. In
B and C, data shown is the average of three separate biological samples generated at the same time. (D) Western blots with the mitochondria
showing the PDK4 protein levels in parental and mesenchymal derivatives. VDAC was used as the protein loading control. The red asterisk denotes
the upper band that specifically corresponds to PDK4. (E) Immunoblotting for PDK4 and EMT markers in A549 parental (Par) and resistant cells.
The resistant clones were generated by culturing A549 cells in the presence of 0.5 μM GDC-0973 and 0.2 μM GDC-0941 for 2 months. Data from
two independent clones is shown. (F, G) HCC827 parental and mesenchymal cells were infected with lentivirus expressing RFP or PDK4 with a
GFP reporter. The GFP-positive cells were selected by FACS, cultured in growth media containing 13C-U-glucose overnight, and then subjected to
LC-MS analysis. (F) Glucose to TCA cycle/glutamate contributions were plotted based on the percentages of (M + 2) citrate, (M + 2) malate and
(M + 2) glutamate in each metabolite’s respective total pool. (G) Pyruvate to glutamate contribution was plotted based on the ratio of glucose→
glutamate (the percentage of (M + 2) glutamate in total glutamate pool) over glucose→ pyruvate (the percentage of (M + 3) pyruvate in total
pyruvate pool). Pyruvate to citrate or malate contribution was similarly plotted. Data are plotted as mean ± SEM. **p < 0.01.
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levels. Of note, we were only able to reliably detect en-
dogenous PDK4 protein using isolated mitochondria
preparations. In addition to lung cancer cell lines, we
examined the pancreatic cancer cell line PANC-1 as well
as the mammary cell line MCF10A and its oncogenically
transformed derivative MCF10AT. All of these cell lines
have previously been reported to undergo TGFβ-induced
EMT [22,23] and similarly demonstrated decreased PDK4
expression following TGFβ treatment (Additional files 4:
Figure S2B, C). We also analyzed the time-course of TGFβ
treatment and observed decreased PDK4 mRNA levels
as early as 30′ after TGFβ treatment (Additional files 4:
Figure S2D, E), suggesting that PDK4 is regulated by
TGFβ signaling at the mRNA level and that PDK4
downregulation is likely an early event in the induction
of EMT by TGFβ.
We next examined whether the decreased expression
of PDK4 may be relevant in other models in which EMT
was not directly induced by TGFβ. A549 cells that had
been rendered resistant to a combination of MEK and
PI3K inhibitors (GDC-0973 and GDC-0941, respect-
ively; Shiuh-Ming Luoh and Marcia Belvin, unpublished
data) displayed hallmark features of EMT, including in-
creased expression of Vimentin and N-cadherin as well
as decreased expression of E-cadherin (Figure 2E). In
this model, we similarly observed dramatically reduced
PDK4 expression in the resistant, mesenchymal deriva-
tives (Figure 2E).
Finally, we re-introduced PDK4 into the mesenchymal
derivative of the HCC827 cells and found that PDK4 over-
expression completely reversed glucose diversion to the
TCA cycle/glutamate (Figure 2F), indicating that PDK4
loss is indeed responsible for the diversion of glucose to
the TCA cycle. Consistent with PDK4’s functional role in
such metabolic rewiring, we also anticipated and observed
increased PDH activity in the mesenchymal cells as shown
by the increased contribution of pyruvate to the TCA
cycle/glutamate (Figure 2G). This diversion of pyruvate tothe TCA cycle/glutamate was similarly rescued following
PDK4 reintroduction into the mesenchymal derivatives
(Figure 2G). In contrast, we did not observe any changes
in glucose contribution to pyruvate or lactate in the mes-
enchymal derivatives of HCC827 cells (Additional file 4:
Figure S2F). Taken together, these findings strongly impli-
cate the PDH regulatory component PDK4 in EMT.
PDK4 expression partially prevents TGFβ-induced EMT
To determine whether PDK4 plays a functional role dur-
ing EMT, we tested whether ectopic PDK4 expression
would impede EMT. We generated HCC827 cells stably
expressing wild-type or kinase-dead PDK4 (Figure 3A).
Based on the structure of PDK4 [24], we generated two
kinase-dead mutants by mutating the canonical ATP-
binding sites—Glu254Ala, referred to as 254A, and
Lys257Ala/Asp258Ala, referred to as 257AA. Although
we still observed EMT following TGFβ treatment in
cells expressing recombinant PDK4, importantly, wild-
type PDK4 was indeed able to partially block the expres-
sion of the mesenchymal markers Zeb1 and Vimentin,
whereas the kinase-dead mutants of PDK4 could not
impede EMT. These findings suggest that the kinase ac-
tivity of PDK4 is required for its role in EMT.
Inhibiting PDK4 drives an EMT associated with erlotinib
resistance
Next, we asked whether blocking PDK4 was sufficient to
drive EMT. We specifically knocked down PDK4 using a
siRNA smart pool. As shown in Figure 3B, we achieved
efficient PDK4 knockdown in A549 and HCC827 cells at
both the mRNA and protein level. Notably, in A549 cells,
PDK4 knockdown decreased the expression of E-cadherin
and modestly increased the expression of Vimentin and
Zeb1. In HCC827 cells, PDK4 knockdown markedly in-
creased the expression of Vimentin and Zeb1, although it
had no effect on E-cadherin (Figure 3B). To rule out po-
tential off-target effects of the siRNA pool, we performed
a deconvolution analysis and found that at least three
Figure 3 PDK4 inhibition promotes EMT. (A) HCC827 cells were transfected with pCMV6-AC-IRES-GFP vector or pCMV6-PDK4-IRES-GFP (WT,
254A, or 257AA), then cultured in the presence of 1.5 μg/ml puromycin for 3 weeks. After that, the GFP-positive cells were enriched through
FACS, cultured in the presence or absence of 2 ng/ml TGFβ for 10 days, and lysed for immunoblotting. (B) A549 and HCC827 cells were
transfected with siNTC pool no. 2 or siPDK4 pool at 1 day and 3 days post-seeding. Two days after the second transfection, the cells were lysed
for immunoblotting and qRT-PCR. VDAC and GAPDH are protein loading controls for mitochondrial lysate and whole cell lysate, respectively. In
A and B, the red asterisk denotes the upper band that is specific for PDK4. (C, D) HCC827 (C) and HCC4006 (D) cells were transfected with siNTC
pool no. 2 or siPDK4 pool at 20 nM siRNA at 1 day and 3 days post-seeding. Twenty-four hours after the second transfection, the media was
replaced with growth media containing 2 μM erlotinib and cells were continuously cultured in such media with fresh media replenished every 3
to 4 days for 2 to 3 weeks. For the control plates without erlotinib treatment, the day before the second transfection, a fraction of the cells was
re-plated at low density and subjected to a second transfection the next day. At the end of the experiment, cells were stained with crystal violet.
The quantification of colony numbers represents four independent experiments, and for each experiment, the colony number in the siNTC plate
is normalized to that in the siPDK4 plate. Paired t-test was performed for C and D. Data are plotted as mean ± SEM. *p < 0.05; **p < 0.01.
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mRNA levels (Additional file 5: Figure S3A) and E-
cadherin in A549 cells (Additional file 5: Figure S3B).
These same single siRNAs also increased Vimentin and
Zeb1 in HCC827 cells (Additional file 5: Figure S3C, H).
To determine whether downregulation of other PDKs
could also affect EMT, we individually knocked down
PDK1-PDK3 using their respective siRNA smart pool.
Under conditions of comparable knockdown efficiency
(Additional file 5: Figure S3D), while knockdown of these
other PDKs led to a modest effect on the expression of
EMT markers, PDK4 knockdown clearly caused the most
pronounced effect on the expression of classical EMT
markers in A549 (Additional file 5: Figure S3E) and
HCC827 (Additional file 5: Figure S3F) cells.
Accumulating evidence has linked EMT to drug resist-
ance [2-6]. Consistent with these findings, HCC827 cells
that have been experimentally induced to undergo EMT
demonstrate erlotinib resistance (Figure 1C), and con-
versely, HCC827 cells that have been selected for erlotinib
resistance through chronic drug exposure gain mesenchy-
mal features [25]. To address a potential role for PDK4 in
EMT-associated erlotinib resistance, we performed PDK4
RNAi studies and examined colony formation capacity in
the presence of erlotinib in mutant EGFR-driven HCC827
cells. In the absence of erlotinib, PDK4 knockdown had
no inhibitory effect on cell growth (Figure 3C). In con-
trast, PDK4 knockdown significantly promoted colony
formation in the presence of erlotinib (Figure 3C and
Additional file 5: Figure S3G), suggesting that its down-
regulation enhanced erlotinib resistance. This effect was
also most pronounced with PDK4 (Additional file 5:
Figure S3I) compared to other PDKs. Notably, PDK4
knockdown also promoted erlotinib resistance in EGFR-
mutant HCC4006 cells (Figure 3D and Additional file 5:
Figure S3J), although it inhibited their growth in the ab-
sence of erlotinib (Figure 3D). In addition to drug resist-
ance, increased migration and/or invasion are hallmarks
of EMT. We examined the migratory and invasive cap-
acity of these cells using scratch wound and boyden
chamber assays, respectively, and observed increased
migration (Additional file 6: Figure S4A) and invasion
(Additional file 6: Figure S4B) in A549 cells following
PDK4 knockdown. Collectively, these data strongly sug-
gest that PDK4 inhibition can promote erlotinib resist-
ance and EMT.
Considering PDK4’s role as a metabolic inhibitor of
PDH that controls entry into the TCA cycle, we exam-
ined the effect of siPDK4 on metabolism using the
MIDA and Seahorse assays. We observed an increased
contribution to glutamate from glucose (Additional file 7:
Figure S5A) as well as a modestly decreased glycolysis/
OXPHOS ratio (Additional file 7: Figure S5B) in siPDK4
cells, indicating that PDK4 knockdown promotes ametabolic reprogramming event that favors the TCA
cycle. Considering that OXPHOS is more efficient in glu-
cose utilization, we hypothesized that siPDK4 would en-
hance cell survival under low-glucose conditions. Indeed,
in A549 cells in which PDK4 had been knocked down, we
observed a robust increase in cell survival under low-
glucose conditions (Additional file 7: Figure S5C), but only
modestly enhanced survival under low-glutamine condi-
tions (Additional file 7: Figure S5D).
AIF interacts with PDK4 and promotes EMT, erlotinib
resistance, and ROS production
To gain additional insight into PDK4’s role in EMT, we
sought to identify proteins that interact with PDK4.
Considering the very limited information regarding
PDK4-interacting proteins, we performed an unbiased
immunoprecipitation (IP) mass spectrometry experiment
to identify novel PDK4-binding proteins. We transiently
overexpressed FLAG-tagged PDK4 in HEK293T cells and
examined the proteins that specifically bound to PDK4
using IP, followed by mass spectrometry (Additional file 8:
Table S2). Interestingly, AIF was one of the proteins that
showed a prominent interaction with PDK4 (Figure 4A
and Additional file 8: Table S2), which we confirmed by
IP-Western blot analysis (Figure 4B).
Consistent with PDK4’s role in mitochondria, AIF is a
mitochondrial protein that can translocate to the nucleus
and promote caspase-independent apoptosis [26]. Bio-
chemical analysis of AIF has revealed two major functional
domains: 1) a DNA binding domain that promotes chro-
matin condensation and DNA fragmentation and 2) an
oxidoreductase domain that is involved in cellular redox
metabolism and mitochondrial bioenergetics [26]. Of note,
AIF inhibition has also been shown to promote drug re-
sistance to the multi-kinase inhibitor sorafenib and the
IκB kinase inhibitor BMS-345541 in melanoma [27,28].
To establish a potential role for AIF in EMT, we
knocked down AIF using a siRNA smart pool and ob-
served EMT in both A549 and HCC827 cells. Similar to
PDK4, knockdown of AIF resulted in increased Zeb1
and Vimentin (A549 and HCC827 cells) and decreased
E-cadherin (A549 cells) (Figure 4C) and promoted erlo-
tinib resistance (Figure 4D), all of which are consistent
with both AIF and PDK4 having a role in EMT. To rule
out a potential off-target effect of siAIF on EMT, we
deconvoluted the siRNA smart pool in A549 cells and
observed that each of the four individual siRNA oligos
decreased E-cadherin expression (Additional file 9: Figure
S6). Considering AIF’s role in redox regulation, we also
measured reactive oxygen species (ROS) levels and de-
tected increased ROS following knockdown of either
PDK4 or AIF (Figure 4E). These collective data support a
functional requirement for the interaction between AIF
and PDK4 in EMTand associated drug resistance.
Figure 4 AIF interacts with PDK4 and plays a role in EMT. (A) HEK293T cells were transfected with the pCMV6-Entry empty vector or
pCMV6-FLAG-Myc-PDK4. Forty-eight hours post-transfection, the cells were lysed and FLAG IP was performed. Mass spectrometry was performed
to analyze the immunoprecipitates, and the top five proteins identified in the immunoprecipitates are shown. (B) Immunoblotting was performed
with samples prepared as in A to confirm the PDK4-AIF interaction. (C) A549 cells and HCC827 cells were transfected with siNTC pool no. 2, siAIF
pool, or siPDK4 pool at 1 day and 3 days post-seeding, then lysed for immunoblotting. (D) HCC827 cells were transfected with siNTC pool no. 2,
siAIF pool, and siPDK4 pool, treated with erlotinib (erl), and stained with crystal violet as in Figure 3C. (E) HCC827 cells were transfected as in D.
Two days after the second transfection, the cells were stained with CM-H2DCFDA and ROS levels were analyzed using flow cytometry.
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cancer and is frequently down-regulated in human cancer
EMT in cancer cells is associated with increased metas-
tasis and resistance to therapy, leading to poor clinical
prognosis [2]. To determine whether PDK4 expression is
associated with prognosis, we examined PDK4 mRNA
expression in NSCLC clinical samples. We divided lung
adenocarcinoma patient samples into PDK4-high (PDK4
expression above median) and PDK4-low (PDK4 expres-
sion below median). We did not observe any association
between tumor stages and PDK4 expression levels. How-
ever, in three independent studies (GSE42127, GSE8894,
and GSE3141) [29-31], we observed a significant (p = 0.01)
overall association between PDK4-low tumors and poor
prognosis. Thus, lung adenocarcinoma patients whose tu-
mors have low PDK4 expression showed reduced overall
survival (Figure 5A).
We further examined PDK4 expression levels in NSCLC
biopsies from the Cancer Genome Atlas (TCGA) using
RNA-seq data. We observed dramatically decreased PDK4
in lung cancer biopsies compared to the corresponding
normal tissue (Figure 5B). Of the two different NSCLC
subtypes, adenocarcinoma (ADC) and squamous cell
carcinoma (SCC), we found that PDK4 expression was
particularly low in SCC, a subtype lacking good treat-
ment options.
To explore PDK4 expression levels in a broad range of
cancer types, we surveyed Gene Logic microarray data
covering multiple types of human tumor biopsies andnormal tissues. Most notably, we observed dramatically
decreased PDK4 expression in the majority of cancer
types examined, including breast, colorectal, lung, lymph-
oid, ovary, and skin cancers (Figure 5C). Finally, we
analyzed the global gene expression changes of 19 cancer
types compared to corresponding normal tissue in the
Gene Logic database. We ranked the approximately 19,000
genes according to the average fold-change and found that
PDK4 was one of the genes that showed the most dramatic
expression loss in cancer (ranked no. 28 overall, data not
shown).
Discussion
Cancer cells preferably use aerobic glycolysis to generate
energy, which has been recognized as a hallmark of can-
cer. Our findings reveal a metabolic rewiring event that
drives cancer cells back to an OXPHOS state during the
process of EMT or during the acquisition of drug resist-
ance. This observation is consistent with three recent
studies: Firstly, Haq et al. reported that BRAF inhibitor-
resistant cells are more addicted to OXPHOS [32]; sec-
ondly, Roesch et al. demonstrated that the multi-drug
resistant JARID1Bhigh subpopulation of melanoma cells
expressed more OXPHOS enzymes [33]; and most re-
cently, Viale et al. showed that pancreatic tumor cells
surviving oncogene ablation depend on mitochondria
[34]. In this study, we analyzed metabolic activity, me-
tabolite profiles, and mass isotopologue distribution to
reveal that cancer cells that have undergone EMT divert
Figure 5 PDK4-low is associated with poor prognosis in human NSCLC, and PDK4 is frequently downregulated in human cancer.
(A) Kaplan-Meier survival analysis of three independent lung adenocarcinoma patient cohorts shows that PDK4-low expression is associated with
poor prognosis. Patients were stratified into PDK4-high (blue line, PDK4 expression above median) and PDK4-low (red line, PDK4 expression below
median). Cox hazard ratios of both the individual studies and the meta-analysis of all three studies together are shown. (B) PDK4 mRNA levels in
normal tissue, adenocarcinoma (ADC) and squamous cell carcinoma (SCC) of the lung. The data are from RNA-seq analysis of the TCGA NSCLC
samples. Data are plotted as mean ± SEM. **p < 0.01. (C) PDK4 mRNA levels in multiple cancer types and their corresponding normal tissues from
the Gene Logic database. The fold-change between the mean tumor and the mean normal tissue expression is shown in the bar plot on a
log2-transformed scale. Significance was determined using a two-tailed t-test. Expression levels are shown in the boxplot on a log2-transformed
scale, with display of the median expression level. The box represents 25–75 % percentile. For all indications shown in C, p < 0.05.
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tal epithelial cells, which presumably enables the mesen-
chymal cells to use the metabolites of the TCA cycle as
the backbone to produce more amino acids. We further
speculate that the increased supply of macromolecules
provides the building blocks for de novo protein synthesis
and extracellular matrix remodeling, which is essential for
EMT [35]. Additionally, since OXPHOS is a more efficientprocess for energy production, shifting to OXPHOS might
enhance the ability of cancer cells to survive under condi-
tions of stress, such as drug treatment.
Our study reveals PDK4 as a novel metabolic regulator
of EMT and drug resistance. A previous study compar-
ing basal and luminal subtypes of breast cancer demon-
strated loss of the metabolic enzyme FBP1 in the more
mesenchymal, basal subtype; however, inhibition of FBP1
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FBP1, we show that inhibition of PDK4 alone is sufficient
to induce EMT, and ectopic expression of PDK4 could
partially prevent TGFβ-induced EMT, although PDK4 is
not differentially expressed between the basal and luminal
subtypes of breast cancer (data not shown). As a pheno-
typic readout of EMT, drug resistance is also enhanced by
PDK4 knockdown. In the absence of drug, PDK4 inhib-
ition does not promote, and even inhibits, cell growth in
some cell lines; in the presence of erlotinib, PDK4 inhib-
ition dramatically promotes colony formation. This
functional profile is reminiscent of a recent study exam-
ining MED12, a component of the transcriptional ME-
DIATOR complex that regulates TGFβ receptor II [13].
Similar to PDK4 inhibition, MED12 inhibition impeded
cell growth in the absence of drug, but promoted colony
formation in the presence of drug. Whereas MED12
regulates TGFβ signaling, PDK4 appears to be regulated
by TGFβ signaling.
Four isoforms of PDK (PDK1-PDK4) with similar
structure negatively regulate the activity of PDH. PDK4
may have some unique functions and may also be sub-
ject to distinct regulatory mechanisms from those affect
PDK1-3. PDK4 expression has been shown to be regu-
lated by various metabolic stimuli (such as starvation,
exercise, and diabetes), the transcription factors FOXO
and E2F1 [20], and epigenetic mechanisms such as pro-
moter methylation and histone acetylation [37,38]. Al-
though PDK1 and PDK2 have been previously proposed
as cancer drug targets [39,40], our findings suggest that
PDK4 may function as a metabolic tumor suppressor.
We observed that depletion of PDK4 by RNAi promoted
colony formation in EGFR-mutant cell lines upon EGFR
inhibition. Conversely, Grassian et al. reported that PDK4
overexpression suppressed the proliferation of normal
mammary epithelial MCF10A cells [41]. In that study, in-
creased PDK4 levels and decreased flux through PDH was
induced upon extracellular matrix (ECM) detachment,
leading to the metabolic impairment of these cells. The
fact that PDK4 emerged as a key factor during EMT in
our study further establishes the role of this enzyme in
regulating ECM/tumor crosstalk and bioenergetics. Sig-
nificantly, we observed widespread loss of PDK4 expres-
sion in tumor cells compared to normal tissue. This loss
of PDK4 expression in cancer is more substantial and
prevalent than that of most known tumor suppressors,
and collectively, these findings suggest that PDK4 may
function as a metabolic tumor suppressor, a possibility
that would need to be further explored in an in vivo
tumorigenesis study.
The mechanism(s) by which PDK4 regulates EMT and
drug resistance is not completely clear. We speculate
that PDK4 depletion plays a role in the survival of drug-
tolerant persisters, but may not be essential for theproliferative expansion of these cells. Furthermore, since
PDK4 knockdown induces Zeb1 expression, PDK4 likely
functions upstream of the EMT-associated transcription
factors. Our data also suggest a novel interaction be-
tween AIF and PDK4, both physically and functionally.
We show the knockdown of either AIF or PDK4 pro-
moted EMT, erlotinib resistance, and ROS production.
Indeed, AIF inhibition has been previously shown to
promote resistance to serum deprivation-induced cell
death in embryonic stem cells [42] as well as to a multi-
kinase inhibitor and an IκB kinase inhibitor in melanoma
[27,28]. A hypothesis that remains to be tested is that
PDK4 or AIF inhibition promotes EMT and drug resist-
ance through ROS generation, especially given the estab-
lished role of ROS in physiological conditions [43,44].Conclusions
Our collective observations implicate a glycolysis-to-
OXPHOS shift in drug-resistant cancer cells that have
undergone EMT. We provide evidence that downregula-
tion of PDK4 is responsible for such metabolic rewiring,
is sufficient to drive EMT, and promotes erlotinib resist-
ance in EGFR mutant lung cancer cells. In addition, we
have identified a novel PDK4-interacting protein, AIF,
which plays a role in EMT and drug resistance. Finally,
analysis of human lung adenoma tumor samples reveals
PDK4-low as a predictor of poor prognosis, consistent with
PDK4’s role in EMT. Although establishing the precise
mechanism by which PDK4 regulates EMT will require
further investigation, the findings described here implicate
a specific metabolic reprogramming event in EMT associ-
ated with resistance to cancer treatments, thereby revealing
novel potential therapeutic opportunities.Additional files
Additional file 1: Extended Methods.
Additional file 2: Figure S1. Metabolic rewiring is observed during
EMT. (A) EGFR-mutant HCC4006 cells were cultured in the presence of
erlotinib (erl) for 3 months to establish erlotinib resistance. The Glycolysis/
OXPHOS ratio of the HCC4006 parental and erl-resistant cells (plotted as
PPR/OCR), as measured by the Seahorse metabolic analyzer. Technical
replicates from six wells of a 96-well plate are shown, and the experiment
was repeated twice. **, p < 0.01. (B, C) Summary from global metabolomic
profiling of cells treated as in Figure 1. See Table S1 for the complete
metabolomics data. (B) The ten metabolites that changed consistently
upon EMT across the three tested cell line models. (C) Changes in cellular
amino acid levels after EMT in three tested cell line models. (D) The growth
rates of the parental cells and their corresponding mesenchymal derivatives.
Cell density (%) was recorded by IncuCyte every 4 hours. (E) Parental (P)
cells and corresponding mesenchymal (M) derivatives were incubated with
growth media containing 13C-U-glutamine overnight, and then subjected
to LC-MS. Glutamine to glutamate contribution was plotted based on the
percentage of (M + 5) glutamate in the total glutamate pool. Each data point
is from three to five separate biological samples generated at the same time.
Data are plotted as mean +/−SEM. **, p < 0.01.
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http://www.cancerandmetabolism.com/content/2/1/20Additional file 3: Table S1. Global metabolomic profiling of the
parental and mesenchymal derivatives of A549, HCC827 and
NCI-H358 cells.
Additional file 4: Figure S2. PDK4 is down-regulated during EMT. (A)
Differentially expressed metabolism-associated genes before and after
EMT in three NSCLC lines based on the microarray analysis. (B) PDK4
mRNA levels in pancreatic cancer cell line PANC1 before (Parental, P) and
after (Mesenchymal, M) TGFβ-induced EMT. (C) PDK4 mRNA levels in
normal breast epithelial cell line MCF10A and its tumorigenic derivative
MCF10AT cells before (Parental, P) and after (Mesenchymal, M) TGFβ-
induced EMT. (D, E) Time course of PDK4 mRNA levels in response to
TGFβ treatment in A549 cells (D) and HCC827 cells (E). PDK4 mRNA levels
were quantified by qRT-PCR. (F) Cells were treated and analyzed as in
Figure 2F. Glucose to pyruvate or lactate contribution was plotted based
on the percentage of (M + 3) pyruvate or (M + 3) lactate in the total
pyruvate or lactate pool, respectively.
Additional file 5: Figure S3. Deconvolution of the siPDK4 smart pool,
and the effects of PDK1-PDK3 knockdown on EMT. (A-C) A549 and
HCC827 cells were transfected with siPDK4 pool or three individual
siRNAs from the pool at one day and three days post-seeding. Two days
after the second transfection, the cells were lysed for immunoblotting
and qRT-PCR. (A) PDK4 knockdown (k/d) efficiency from individual siRNAs
in A549 cells, evaluated using qRT-PCR. (B) Immunoblots showing the
effects of PDK4 knockdown on the epithelial marker E-cadherin in A549
cells, using three individual siRNAs. (C) Immunoblots showing the effects
of PDK4 knockdown on mesenchymal markers Vimentin and Zeb1 in
HCC827 cells, using three individual siRNAs. (D-F) A549 and HCC827 cells
were transfected with siRNA smart pools of siNTC, siPDK1, siPDK2, siPDK3
or siPDK4 at one day and three days post-seeding. (D) Validation of
knockdown (k/d) efficiency of each PDK siRNA on the corresponding
PDK isoform, quantified by qRT-PCR. The y-axis represents the particular
PDK mRNA levels in siPDK-transfected cells over siNTC-transfected cells.
(E) Immunoblots showing the effects of each PDK isoform knockdown on
the epithelial marker E-cadherin in A549 cells. (F) Immunoblots showing the
effects of each individual PDK isoform knockdown on the mesenchymal
markers Vimentin and Zeb1 in HCC827 cells. (G) Colony formation capacity
of HCC827 cells treated as in C, in the presence of 2 μM erlotinib. (H) PDK4
knockdown (k/d) efficiency using individual siRNAs in HCC827 cells, as
evaluated in A. (I) Colony formation capacity of HCC827 cells treated in
F, in the presence of 2 μM erlotinib. The siNTC and siPDK4 plates in I are
reproduced from Figure 3C to facilitate a direct comparison amongst all
parameters. (J) Colony formation capacity of HCC4006 cells treated as in G,
in the presence of 2 μM erlotinib.
Additional file 6: Figure S4. PDK4 knockdown promotes cell migration
and invasion. A549 cells were transfected with siNTC pool#2 or the
siPDK4 pool at one day and three days post-seeding. The day after the
second transfection, cells were seeded in an IncuCyte ImageLock plate
for migration assay (A), and a Boyden chamber for invasion assay (B), as
described in the Extended Methods. The migration assay shows the
average of 10 wells from one experiment, which is representative of two
independent experiments. The invasion assay is the average of two
independent experiments each containing two replicates. *, p < 0.05.
Additional file 7: Figure S5. PDK4 knockdown promotes metabolic
rewiring and cell survival under low glucose conditions. HCC827 cells
were transfected with siNTC pool#2 or the siPDK4 pool at one day and
three days post-seeding. (A) The day after the second transfection,
the cells were incubated overnight with growth media containing
13C-U-glucose, and then subjected to LC-MS. Glucose to glutamate
contribution was plotted based on the percentage of (M + 2) glutamate
in the total glutamate pool. Each data point is from three separate
biological samples generated at the same time. (B) The day after the
second transfection, the cells were seeded in Seahorse plates to measure
Glycolysis/OXPHOS ratio (defined by PPR/OCR). Each data point is from
eight wells. (C, D) The day after the second transfection, cells were plated
in 96 well plates. After overnight incubation, cells were switched to
media containing various concentrations of glucose (C) or glutamine (D).
Three days after, cell survival was measured using CellTiterGlo. Each data
point is an average of three wells. Data are plotted as mean +/−SEM.
*, p < 0.05, **, p < 0.01.Additional file 8: Table S2. Proteins identified in the FLAG-PDK4
immunoprecipitates by mass spectrometry analysis.
Additional file 9: Figure S6. Deconvolution of the siAIF smart pool.
A549 cells were transfected with siNTC pool#2, the siAIF smart pool, or
individual siRNAs in the siAIF smart pool, at one day and three days
post-seeding, then lysed for immunoblotting.
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